文献速递消化系统肿瘤

奥沙利铂、5-氟尿嘧啶与白蛋白结合型紫杉醇作为可切除胃腺癌围手术期方案:GERCOR II期研究(FOXAGAST)

Oxaliplatin, 5-Fluorouracil and Nab-paclitaxel as perioperative regimen in patients with resectable gastric adenocarcinoma: A GERCOR phase II study (FOXAGAST).
PubMed 文献 · Eur J Cancer · 2018-12-07

这项非随机、开放标签的II期研究纳入49例可切除胃腺癌患者,术前接受白蛋白结合型紫杉醇联合FOLFOX方案每2周一次、共6个周期。主要终点TRG1率为16.3%,达到预设的拒绝H0标准;3级及以上毒性可控,但术后手术相关并发症发生率为31.8%,作者认为该方案值得在III期研究中进一步探索。

要点

  • 49例可切除胃腺癌患者接受围手术期白蛋白结合型紫杉醇联合FOLFOX,TRG1率为16.3%。
  • 5例(10.2%)未能手术,44例中R0切除42例(95.5%),手术相关并发症14例(31.8%)。
  • 新辅助期3级及以上毒性以非发热性中性粒细胞减少(20.4%)最常见,作者认为该方案值得在III期研究中探索。

核心结论

  • 作者认为该围手术期方案显示出有前景的抗肿瘤活性,毒性可控,但观察到比例不低的手术并发症,值得在III期研究中进一步探索。

研究设计与样本

  • 非随机、开放标签的II期研究(GERCOR),纳入49例可切除胃腺癌患者。
  • 患者接受新辅助白蛋白结合型紫杉醇150 mg/m2联合FOLFOX每2周一次、共6个周期,术后是否再行6个周期由研究者决定。
  • 主要终点为病理完全缓解(TRG1)率,按Fleming设计需49例检验H0(10% TRG1)与H1(25% TRG1),TRG1达8例可拒绝H0。

主要发现

  • 新辅助化疗周期数中位为6(范围3-6);白蛋白结合型紫杉醇、奥沙利铂和5-FU的中位剂量强度分别为96%(38-103%)、97%(47-103%)和99%(50-112%)。
  • 5例(10.2%)未能手术;44例中R0切除42例(95.5%)。
  • 病理TRG1至TRG5分别为8例(16.3%)、11例(22.5%)、4例(8.2%)、18例(36.7%)和3例(6.1%)。
  • 新辅助化疗期间3级及以上毒性为非发热性中性粒细胞减少(20.4%)、恶心(8.2%)、腹泻(8.2%)和神经病变(6.1%)。
  • 44例中14例(31.8%)出现手术相关并发症,3例(6.8%)死于手术并发症。

关键数值与推荐

  • 主要终点TRG1率为16.3%(8例),达到预设拒绝H0所需8例的界值。
  • R0切除率为95.5%(42/44),未能手术比例为10.2%(5例)。
  • 新辅助期3级及以上非发热性中性粒细胞减少20.4%、恶心8.2%、腹泻8.2%、神经病变6.1%。
  • 手术相关并发症31.8%(14/44),手术并发症死亡6.8%(3/44)。

临床怎么用

  • 作者认为该围手术期方案活性有前景、毒性可控,但手术并发症比例不容忽视,值得在III期研究中进一步评估。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: 5-Fluorouracil (5-FU) and platinum-based perioperative chemotherapy is standard of care for resectable gastric adenocarcinoma (RGA). Nanoparticle albumin-bound (Nab-) paclitaxel is active in advanced disease but has never been evaluated in the perioperative setting. The objective was to evaluate the efficacy of Nab-paclitaxel in combination with FOLFOX for RGA patients. METHODS: We performed a non-randomised, open-label, phase II study. RGA patients were assigned to receive neoadjuvant Nab-paclitaxel (150 mg/m2) and FOLFOX q2w for six cycles. Six additional post-operative cycles were kept at the investigator's discretion. The primary end-point was complete pathological response (tumour regression grade [TRG1]) rate. According to Fleming design, 49 patients were required to test H0 (10% TRG1) and H1 (25% TRG1). To reject H0, TRG1 had to be achieved in 8 patients. RESULTS: Forty-nine patients were included. Median number of neoadjuvant chemotherapy cycles was 6 (range, 3-6). Median dose intensity for Nab-paclitaxel, oxaliplatin and 5-FU was 96% (38-103%), 97% (47-103%) and 99% (50-112%), respectively. Surgery could not be performed in 5 (10.2%) patients. Tumour resection was R0 for 42 of 44 (95.5%) patients. Pathological review classified tumours as TRG1 to TRG5 for 8 (16.3%), 11 (22.5%), 4 (8.2%), 18 (36.7%) and 3 (6.1%) patients, respectively. Grade 3 or worse toxicities during neoadjuvant chemotherapy were non-febrile neutropenia (20.4%), nausea (8.2%), diarrhoea (8.2%) and neuropathy (6.1%). Of 44 patients, 14 (31.8%) experienced surgery-related complications and three (6.8%) died of surgical complications. CONCLUSION: This regimen shows promising activity. Toxicity is manageable but a meaningful rate of surgical complications was observed. This strategy deserves investigation in phase III studies.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Watson S, de la Fouchardière C, Kim S, et al. Oxaliplatin, 5-Fluorouracil and Nab-paclitaxel as perioperative regimen in patients with resectable gastric adenocarcinoma: A GERCOR phase II study (FOXAGAST). Eur J Cancer. 2018. PMID: 30529902. doi:10.1016/j.ejca.2018.11.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。